Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totaling 1,116,504 shares, a growth of ∞ from the May 31st total of 0 shares. Based on an average daily volume of 838,555 shares, the short-interest ratio is presently 1.3 days. Currently, 0.9% of the company’s shares are sold short.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised Parabilis Medicines to a “hold” rating in a research note on Saturday, June 20th.
View Our Latest Stock Report on Parabilis Medicines
Parabilis Medicines Price Performance
Insider Transactions at Parabilis Medicines
In other news, major shareholder Guy Levy acquired 500,000 shares of Parabilis Medicines stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This represents a 94.88% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Sebulsky acquired 9,065 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $26.49 per share, for a total transaction of $240,131.85. Following the acquisition, the director directly owned 30,000 shares of the company’s stock, valued at approximately $794,700. The trade was a 43.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 530,000 shares of company stock valued at $10,723,528.
Featured Articles
- Five stocks we like better than Parabilis Medicines
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
